Oil rises above $49 as vaccine release spurs demand hopes

Send a link to a friend  Share

[December 10, 2020] By Alex Lawler

LONDON (Reuters) -Oil rose above $49 a barrel on Thursday as hopes of a faster demand recovery after the release of COVID-19 vaccines offset a huge rise in U.S. crude inventories that showed there was still ample supply available.

 

Britain began vaccinations this week and they could start as soon as this weekend in the United States. Canada on Wednesday approved its first vaccine and said initial shots would be delivered starting next week.

Brent crude was up 51 cents, or 1%, at $49.37 a barrel at 1039 GMT, rising for a third day. U.S. West Texas Intermediate (WTI) crude rose 45 cents, or 1%, to $45.97.

Oil gained even after the latest weekly report on U.S. oil inventories showed a massive, 15.2 million-barrel rise in crude stocks. Analysts had expected a 1.4 million-barrel drop. [EIA/S]

"The latest set of data has exceeded any bearish expectations," said Tamas Varga of oil broker PVM. "The stubbornness of oil bulls and their confidence in the positive economic impact of the vaccine roll-out are truly remarkable."

Concern over an attack on an Iraqi oilfield also lent support. Two wells at a small field were set ablaze by explosives on Wednesday, but overall production from the field was not affected.

"Traders are also nervous about the oil supply," said Naeem Aslam of Avatrade, referring to the Iraq attack.

Oil has recovered from historic lows reached in April when the pandemic hammered demand, helped by a record supply-cut deal by the Organization of the Petroleum Exporting Countries and allies, known as OPEC+.

OPEC+ will further ease its supply restrictions in January by adding an extra 500,000 barrels per day although the easing is more gradual than previously agreed, to provide additional support to the market.

(Additional reporting by Sonali Paul and Florence Tan; Editing by Mark Potter and David Clarke)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

 

 

Back to top